Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Sworder BJ, et al. Among authors: duhrsen u. Cancer Cell. 2023 Jan 9;41(1):210-225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584673 Free PMC article.
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Wiegers SE, Pieplenbosch S, Chamuleau MED, Lugtenburg PJ, de Jong D, Ylstra B, Mendeville M, Dührsen U, Hanoun C, Hüttmann A, Richter J, Klapper W, Jauw YWS, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: duhrsen u. Blood Adv. 2023 Jan 24;7(2):214-223. doi: 10.1182/bloodadvances.2022008629. Blood Adv. 2023. PMID: 36306337 Free PMC article.
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: duhrsen u. Blood. 2023 Jun 22;141(25):3055-3064. doi: 10.1182/blood.2022018558. Blood. 2023. PMID: 37001036 Free PMC article.
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients.
Ferrández MC, Golla SSV, Eertink JJ, de Vries BM, Lugtenburg PJ, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, Kurch L, Hüttmann A, Hanoun C, Dührsen U, de Vet HCW; PETRA; Zijlstra JM, Boellaard R. Ferrández MC, et al. Among authors: duhrsen u. Sci Rep. 2023 Aug 12;13(1):13111. doi: 10.1038/s41598-023-40218-1. Sci Rep. 2023. PMID: 37573446 Free PMC article.
Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.
Ferrández MC, Golla SSV, Eertink JJ, Wiegers SE, Zwezerijnen GJC, Heymans MW, Lugtenburg PJ, Kurch L, Hüttmann A, Hanoun C, Dührsen U, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Zijlstra JM, Boellaard R; PETRA Consortium. Ferrández MC, et al. Among authors: duhrsen u. J Nucl Med. 2024 Nov 1;65(11):1802-1807. doi: 10.2967/jnumed.124.268191. J Nucl Med. 2024. PMID: 39362767
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma.
Mendeville MS, Janssen J, Los-de Vries GT, van Dijk E, Richter J, Nijland M, Roemer MGM, Stathi P, Hijmering NJ, Bladergroen R, Pelaz DA, Diepstra A, Eertink CJ, Burggraaff CN, Kim Y, Lugtenburg PJ, van den Berg A, Tzankov A, Dirnhofer S, Dührsen U, Hüttmann A, Klapper W, Zijlstra JM, Ylstra B, de Jong D. Mendeville MS, et al. Among authors: duhrsen u. Nat Commun. 2025 Jan 2;16(1):109. doi: 10.1038/s41467-024-55614-y. Nat Commun. 2025. PMID: 39747123 Free PMC article.
Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker.
Johansson P, Laguna T, Ossowski J, Pancaldi V, Brauser M, Dührsen U, Keuneke L, Queiros A, Richter J, Martín-Subero JI, Siebert R, Schlegelberger B, Küppers R, Dürig J, Murga Penas EM, Carillo-de Santa Pau E, Bergmann AK. Johansson P, et al. Among authors: duhrsen u. Clin Epigenetics. 2022 Nov 14;14(1):148. doi: 10.1186/s13148-022-01362-z. Clin Epigenetics. 2022. PMID: 36376973 Free PMC article.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
Publisher Correction: Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarker.
Johansson P, Laguna T, Ossowski J, Pancaldi V, Brauser M, Dührsen U, Keuneke L, Queiros A, Richter J, Martín-Subero JI, Siebert R, Schlegelberger B, Küppers R, Dürig J, Penas EMM, Pau ECS, Bergmann AK. Johansson P, et al. Among authors: duhrsen u. Clin Epigenetics. 2023 Jan 6;15(1):3. doi: 10.1186/s13148-022-01405-5. Clin Epigenetics. 2023. PMID: 36609404 Free PMC article. No abstract available.
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.
Frontzek F, Renaud L, Dührsen U, Poeschel V, Bernard S, Chartier L, Ketterer N, Récher C, Fitoussi O, Held G, Casasnovas O, Haioun C, Mounier N, Tilly H, Morschhauser F, Le Gouill S, Karsten IE, Duns G, Steidl C, Scott DW, Klapper W, Rosenwald A, Ott G, Molina T, Lenz G, Ziepert M, Altmann B, Thieblemont C, Schmitz N. Frontzek F, et al. Among authors: duhrsen u. Leukemia. 2024 Oct;38(10):2225-2234. doi: 10.1038/s41375-024-02371-y. Epub 2024 Aug 16. Leukemia. 2024. PMID: 39152324 Clinical Trial.
329 results